共查询到20条相似文献,搜索用时 15 毫秒
1.
2.
3.
4.
5.
L Raycroft J R Schmidt K Yoas M M Hao G Lozano 《Molecular and cellular biology》1991,11(12):6067-6074
6.
7.
Peidis P Voukkalis N Aggelidou E Georgatsou E Hadzopoulou-Cladaras M Scott RE Nikolakaki E Giannakouros T 《FEBS letters》2011,585(1):78-84
A significant amount of nuclear p53 is found associated with the nuclear matrix in cells that were exposed to genotoxic stress. In this study we identified Scaffold attachment factor B1 (SAFB1), a nuclear matrix-associated protein that binds the scaffold or matrix attachment regions (S/MARs) of genomic DNA, as a novel p53-interacting protein. SAFB1 was able to associate with p53 through its C-terminal domain, while significant co-localization of the two proteins was observed in cells treated with 5-fluorouracil or mithramycin. Binding of p53 to SAFB1 had a significant functional outcome, since SAFB1 was shown to suppress p53-mediated reporter gene expression. These data suggest that nuclear matrix-associated proteins may play a critical role in regulating p53 localization and activity.
Structured summary
p53physically interacts with SRPK1a: shown by two hybrid (view interaction)p53physically interacts with SRPK1a: shown by pull down (view interaction)p53physically interacts with SRPK1a: shown by anti bait coimmunoprecipitation (view interaction)p53physically interacts with SRPK1a: shown by anti tag coimmunoprecipitation (view interaction)SAFB1physically interacts with p53: shown by pull down (view interactions 1, 2)SAFB1physically interacts with p53: shown by anti bait coimmunoprecipitation (view interactions 1, 2)SAFB1 and p53colocalize: shown by fluorescence microscopy (view interaction)SAFB2physically interacts with p53: shown by pull down (view interaction) 相似文献8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
Yuhao Liu Ziyi Wang Chao Ma Zhenquan Wei Kai Chen Chao Wang Chi Zhou Leilei Chen Qingwen Zhang Zhenqiu Chen Wei He Jiake Xu 《Journal of cellular and molecular medicine》2020,24(6):3303-3313
Osteolytic skeletal disorders are caused by an imbalance in the osteoclast and osteoblast function. Suppressing the differentiation and resorptive function of osteoclast is a key strategy for treating osteolytic diseases. Dracorhodin perchlorate (D.P), an active component from dragon blood resin, has been used for facilitating wound healing and anti-cancer treatments. In this study, we determined the effect of D.P on osteoclast differentiation and function. We have found that D.P inhibited RANKL-induced osteoclast formation and resorbed pits of hydroxyapatite-coated plate in a dose-dependent manner. D.P also disrupted the formation of intact actin-rich podosome structures in mature osteoclasts and inhibited osteoclast-specific gene and protein expressions. Further, D.P was able to suppress RANKL-activated JNK, NF-κB and Ca2+ signalling pathways and reduces the expression level of NFATc1 as well as the nucleus translocation of NFATc1. Overall, these results indicated a potential therapeutic effect of D.P on osteoclast-related conditions. 相似文献
19.
20.